Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

Documenti analoghi

• EGFR targeted nanobody–photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer
  di: van Driel, Pieter B.A.A., et al.
  Pubblicazione: (2016)
• Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy
  di: Mashayekhi, Vida, et al.
  Pubblicazione: (2020)
• Acute cellular and vascular responses to photodynamic therapy using EGFR-targeted nanobody-photosensitizer conjugates studied with intravital optical imaging and magnetic resonance imaging
  di: de Bruijn, Henriette S., et al.
  Pubblicazione: (2020)
• Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a Near-Infrared Fluorescent Anti–Epidermal Growth Factor Receptor Nanobody
  di: Sabrina Oliveira, et al.
  Pubblicazione: (2012-01-01)
• The Potential of Nanobody-Targeted Photodynamic Therapy to Trigger Immune Responses
  di: Beltrán Hernández, Irati, et al.
  Pubblicazione: (2020)